teprotumumab + recombinant human hyaluronidase

Teprotumumab + recombinant human hyaluronidase is a combination therapy that would consist of **teprotumumab**, a fully human monoclonal antibody targeting the insulin-like growth factor I receptor (IGF-IR), and **recombinant human hyaluronidase**, an enzyme designed to temporarily increase subcutaneous tissue permeability by degrading hyaluronan. Teprotumumab acts as an antagonist at IGF-IR, inhibiting signaling pathways involved in the pathology of thyroid eye disease (thyroid-associated ophthalmopathy). Recombinant human hyaluronidase facilitates the dispersion and absorption of co-administered therapeutics when given subcutaneously, hence improving tissue availability of large biologics. Although teprotumumab is approved for intravenous use in thyroid eye disease, and recombinant human hyaluronidase is used to aid subcutaneous biologic delivery (for example, as in Herceptin Hylecta and Phesgo), there is no specific evidence that this exact combination product (teprotumumab + recombinant human hyaluronidase) is currently marketed or approved. The combination would theoretically enable subcutaneous administration of teprotumumab, potentially offering more convenient delivery for patients.